- Home
- MYNZ vs GLMD Comparison
MYNZ vs GLMD Comparison
Compare MYNZ & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- GLMD
- Stock Information
- Founded
- MYNZ 2021
- GLMD 2000
- Country
- MYNZ Germany
- GLMD Israel
- Employees
- MYNZ N/A
- GLMD N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- GLMD Health Care
- Exchange
- MYNZ Nasdaq
- GLMD Nasdaq
- Market Cap
- MYNZ 7.9M
- GLMD 8.0M
- IPO Year
- MYNZ 2021
- GLMD 2014
- Fundamental
- Price
- MYNZ $1.49
- GLMD $1.37
- Analyst Decision
- MYNZ Buy
- GLMD Hold
- Analyst Count
- MYNZ 2
- GLMD 1
- Target Price
- MYNZ $14.00
- GLMD N/A
- AVG Volume (30 Days)
- MYNZ 499.8K
- GLMD 72.8K
- Earning Date
- MYNZ 09-26-2025
- GLMD 11-13-2025
- Dividend Yield
- MYNZ N/A
- GLMD N/A
- EPS Growth
- MYNZ N/A
- GLMD N/A
- EPS
- MYNZ N/A
- GLMD N/A
- Revenue
- MYNZ $659,935.00
- GLMD N/A
- Revenue This Year
- MYNZ $26.06
- GLMD N/A
- Revenue Next Year
- MYNZ $4.97
- GLMD N/A
- P/E Ratio
- MYNZ N/A
- GLMD N/A
- Revenue Growth
- MYNZ N/A
- GLMD N/A
- 52 Week Low
- MYNZ $1.28
- GLMD $1.15
- 52 Week High
- MYNZ $14.39
- GLMD $4.81
- Technical
- Relative Strength Index (RSI)
- MYNZ 43.48
- GLMD 40.59
- Support Level
- MYNZ $1.28
- GLMD $1.37
- Resistance Level
- MYNZ $1.73
- GLMD $1.50
- Average True Range (ATR)
- MYNZ 0.14
- GLMD 0.10
- MACD
- MYNZ -0.01
- GLMD -0.02
- Stochastic Oscillator
- MYNZ 44.67
- GLMD 6.67
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.